Comparing Nemtabrutinib with Rituximab for leukemia, lymphocytic, chronic, b-cell
Explore this study →
There are 2 groups in this study. Group A receives Nemtabrutinib and Venetoclax. Group B, the comparison group, receives Venetoclax and Rituximab.
Sites in Greenfield Park, Kingston and 2 more cities
- Phase 3
- 2 groups
- Sites in Moncton, Kingston and 2 more cities
- Recruiting
Official title: A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Leukemia, Lymphocytic, Chronic, B-Cell · Merck Sharp & Dohme LLC